Gene therapy and genetic engineering are transforming the landscape of personalized and regenerative medicine by offering precise, targeted corrections at the genetic level. These technologies enable the replacement, repair, or regulation of defective genes using viral or non-viral delivery systems, significantly altering the course of inherited and acquired diseases. In tissue engineering, gene editing plays a pivotal role in programming stem cells, enhancing scaffold-cell interactions, and boosting tissue regeneration. Breakthroughs such as CRISPR-Cas9, base editing, and prime editing allow high-fidelity genomic modifications, minimizing off-target effects and increasing clinical feasibility. Gene therapy and genetic engineering are also being integrated into smart biomaterial systems and synthetic biology platforms to provide controlled release and spatially defined gene expression. As regulatory frameworks adapt, more gene-modified cell and tissue products are entering early-stage trials, suggesting a shift toward curative and adaptive solutions for complex diseases.
Title : Eliminating implants infections with nanomedicine: Human results
Thomas J Webster, Interstellar Therapeutics, United States
Title : Biodistribution and gene targeting in regenerative medicine
Nagy Habib, Imperial College London, United Kingdom
Title : Graphene, butterfly structures, and stem cells: A revolution in surgical implants
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, London NW1 0NH, United Kingdom
Title : Precision in cartilage repair: Breakthroughs in biofabrication process optimization
Pedro Morouco, Polytechnic of Leiria, Portugal
Title : Keratin-TMAO wound dressing promote tissue recovery in diabetic rats via activation of M2 macrophages
Marek Konop, Medical University of Warsaw, Poland
Title : Assessing geometric simplifications in vertebral modeling for reliable numerical analysis of intervertebral discs
Oleg Ardatov, Vilnius University, Lithuania